Selective Estrogen Receptor Modulators

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

Fresh funding is slated to carry the late-stage study toward a mid-2027 readout pending an expected closing next week.